ANI Pharmaceuticals financials
$72.62−2.95%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M | $208.5M | $206.5M | $201.6M | $176.8M | $128.6M |
| Gross profit | $542.1M | $364.2M | $305.3M | $177.6M | $115.5M | $121.3M | $143.4M | $128.6M | $97.8M | $79.8M |
| Gross margin | 61.4% | 59.3% | 62.7% | 56.1% | 53.5% | 58.2% | 69.4% | 63.8% | 55.3% | 62.1% |
| Operating income | $111.5M | -$4.8M | $48.1M | -$29.6M | -$39.8M | -$16.0M | $16.4M | $35.4M | $28.3M | $20.1M |
| Net income | $70.2M | -$20.1M | $15.5M | -$49.5M | -$42.8M | -$22.5M | $6.1M | $15.3M | -$1.1M | $3.9M |
| Net margin | 7.9% | −3.3% | 3.2% | −15.7% | −19.8% | −10.8% | 3.0% | 7.6% | −0.6% | 3.1% |
| Diluted EPS | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 | $0.50 | $1.30 | $-0.09 | $0.34 |
| EBITDA | $203.7M | $70.6M | $107.9M | $33.9M | $19.1M | $29.1M | $61.0M | $69.1M | $57.2M | $49.1M |
| Operating cash flow | $185.2M | $64.0M | $119.0M | -$31.2M | $3.3M | $15.3M | $45.6M | $67.1M | $39.4M | $27.5M |
| Free cash flow | $171.4M | $47.8M | $110.1M | -$40.1M | $765.0K | $9.1M | $39.0M | $61.3M | $29.1M | $22.9M |
| Diluted shares | 21.2M | 19.3M | 18.2M | 16.3M | 12.6M | 12.0M | 12.0M | 11.8M | 11.5M | 11.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $285.6M | $144.9M | $221.1M | $48.2M | $100.3M | $7.9M |
| Short-term investments | $9.1M | $6.3M | $0.00 | $0.00 | — | — |
| Total debt | $617.0M | $624.1M | $285.7M | $286.5M | $287.4M | $185.7M |
| Total assets | $1.44B | $1.28B | $904.4M | $760.1M | $771.6M | $461.2M |
| Total liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M | $265.5M |
| Shareholders' equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M | $195.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology